Cargando…

No evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample

A number of pharmaceuticals have been identified as potential adjuvants to speech language therapy following stroke, but it is also important to consider which pharmaceuticals may result in a less robust recovery. Here we examine whether post-stroke language recovery was meaningfully impeded by chol...

Descripción completa

Detalles Bibliográficos
Autores principales: Stockbridge, Melissa D., Keser, Zafer, Bunker, Lisa D., Hillis, Argye E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231759/
https://www.ncbi.nlm.nih.gov/pubmed/35749406
http://dx.doi.org/10.1371/journal.pone.0270135
_version_ 1784735416522375168
author Stockbridge, Melissa D.
Keser, Zafer
Bunker, Lisa D.
Hillis, Argye E.
author_facet Stockbridge, Melissa D.
Keser, Zafer
Bunker, Lisa D.
Hillis, Argye E.
author_sort Stockbridge, Melissa D.
collection PubMed
description A number of pharmaceuticals have been identified as potential adjuvants to speech language therapy following stroke, but it is also important to consider which pharmaceuticals may result in a less robust recovery. Here we examine whether post-stroke language recovery was meaningfully impeded by cholinergic, GABAergic, or dopaminergic medications patients received. Eighty participants with left hemisphere stroke were examined retrospectively to see whether the use of one of these three classes of medication prior to admission for acute stroke, during their inpatient stay, or at discharge was associated with differences in recovery on three common measures of language. While prescription of any of the candidate drugs was relatively uncommon, groups were very well matched for many common factors that impact performance. When age, education, and acute lesion volume were controlled, there were no significant differences in performance among those taking cholinergic, GABAergic, or dopaminergic medications and those who were not. Those who experienced a “good recovery” of language (≥10% improvement on any one language measure over time) had similar exposure to these drugs to those with a poor recovery. This work represents a first look at these drug classes with regard to their effects on the recovery of language after stroke and should not be interpreted as resolving all potential for concern, but these results do offer modest reassurance that these common classes of pharmacotherapy, when given for short periods in this population, do not appear to have marked deleterious effects on post-stroke recovery of language.
format Online
Article
Text
id pubmed-9231759
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-92317592022-06-25 No evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample Stockbridge, Melissa D. Keser, Zafer Bunker, Lisa D. Hillis, Argye E. PLoS One Research Article A number of pharmaceuticals have been identified as potential adjuvants to speech language therapy following stroke, but it is also important to consider which pharmaceuticals may result in a less robust recovery. Here we examine whether post-stroke language recovery was meaningfully impeded by cholinergic, GABAergic, or dopaminergic medications patients received. Eighty participants with left hemisphere stroke were examined retrospectively to see whether the use of one of these three classes of medication prior to admission for acute stroke, during their inpatient stay, or at discharge was associated with differences in recovery on three common measures of language. While prescription of any of the candidate drugs was relatively uncommon, groups were very well matched for many common factors that impact performance. When age, education, and acute lesion volume were controlled, there were no significant differences in performance among those taking cholinergic, GABAergic, or dopaminergic medications and those who were not. Those who experienced a “good recovery” of language (≥10% improvement on any one language measure over time) had similar exposure to these drugs to those with a poor recovery. This work represents a first look at these drug classes with regard to their effects on the recovery of language after stroke and should not be interpreted as resolving all potential for concern, but these results do offer modest reassurance that these common classes of pharmacotherapy, when given for short periods in this population, do not appear to have marked deleterious effects on post-stroke recovery of language. Public Library of Science 2022-06-24 /pmc/articles/PMC9231759/ /pubmed/35749406 http://dx.doi.org/10.1371/journal.pone.0270135 Text en © 2022 Stockbridge et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Stockbridge, Melissa D.
Keser, Zafer
Bunker, Lisa D.
Hillis, Argye E.
No evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample
title No evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample
title_full No evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample
title_fullStr No evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample
title_full_unstemmed No evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample
title_short No evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample
title_sort no evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231759/
https://www.ncbi.nlm.nih.gov/pubmed/35749406
http://dx.doi.org/10.1371/journal.pone.0270135
work_keys_str_mv AT stockbridgemelissad noevidenceofimpedimentbythreecommonclassesofprescriptiondrugstopoststrokeaphasiarecoveryinaretrospectivelongitudinalsample
AT keserzafer noevidenceofimpedimentbythreecommonclassesofprescriptiondrugstopoststrokeaphasiarecoveryinaretrospectivelongitudinalsample
AT bunkerlisad noevidenceofimpedimentbythreecommonclassesofprescriptiondrugstopoststrokeaphasiarecoveryinaretrospectivelongitudinalsample
AT hillisargyee noevidenceofimpedimentbythreecommonclassesofprescriptiondrugstopoststrokeaphasiarecoveryinaretrospectivelongitudinalsample